Effect of Thalidomide on Nitric Oxide Production in Lipopolysaccharide-activatedRAW 264.7 Cells
April 2010 | Volume 9 | Issue 4 | Original Article | 330 | Copyright © April 2010
Eunkyue Park PhD, William R. Levis MD, Nigel Greig PhD, Euisun Jung DVM,Georgia Schuller-Levis PhD
AbstractThalidomide is anti-inflammatory under some conditions, yet has been reported to up-regulate Th1 (T helper 1) immunity measured by increased IL-2 (Interleukin-2) and gamma interferon. The authors have assessed the effect of thalidomide and analogues, di- and tri-thiothalidomide, on a lipopolysaccharide (LPS) activated macrophage cell line (RAW 246.7 cells). The authorsâ€™ findings showed that nitric oxide (NO) was significantly inhibited by thalidomide (15%) and its analogues (di-thiothalidomide; 15%, tri-thiothalidomide; 32%). The proinflammatory molecules TNF-α (tumor necrosis factor-alpha) and IL-6 were not significantly inhibited. Pretreatment with thalidomide and analogues before activation was not different from simultaneous treatment. Inhibition of inducible nitric oxide synthase (iNOS) may prove to be an important target for the anti-inflammatory and anti-cancer effects of thalidomide and related immunomodulatory drugs (IMiDs).